Auriga Laboratories, Inc.'s Chief Executive Officer Terminates 10b5-1 Trading Plans

LOS ANGELES--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company with products for the treatment of Xerostomia, dermatological conditions, and acute respiratory diseases, announced today that Philip S. Pesin, Auriga’s Chief Executive Officer, has terminated his pre-arranged stock trading plan on August 30, 2007. No further sales under the plan will occur after the planned third quarter sales. The plan was adopted in accordance with guidelines specified under Securities and Exchange Commission (SEC) Rule 10b5-1.